Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Pulmonary Arterial Hypertension (PAH) confirmed by cardiac catheterization.~* Current diagnosis of WHO group 1 PAH with functional class 2, 3, or 4 symptoms.~Exclusion Criteria:~* Has portal hypertension or chronic liver disease.~* Has history of left sided heart disease or significant cardiac disease.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sitaxsentan (Type: EXPERIMENTAL): Sitaxsentan

Based on this trial design, predict the completion outcome and termination type (if applicable).